Category
Blog
-
2023
-
AstraZeneca, Amgen’s asthma launch Tezspire picks up backing from England’s NICE
-
EU Approves Amicus Therapeutics Pombiliti for Late-Onset Pompe Disease
-
Viatris, Cipla and Aurobindo sign up to make generics of GSK’s long-acting HIV PrEP drug
-
EMA Highlights Trial Innovation, Real-World Data Advances
-
Camber Pharmaceuticals Recalls Antifungal Drug Due to Contamination Risk
-
Eisai Presents New Phase 3 Analyses of ARIA and Quality of Life of Lecanemab-Treated Patients
-
Enrollment and Topline Data Expected Sooner for Phase 3 Trial of Pitolisant in Idiopathic Hypersomnia
-
Caribou’s CAR-T cell therapy receives fast track status
-
Signs of change in Korean diabetes treatment market
-
Shionogi secures fast track designation for investigational Covid-19 drug